Frank Joseph W, Levy Cari, Calcaterra Susan L, Hoppe Jason A, Binswanger Ingrid A
Division of General Internal Medicine, University of Colorado School of Medicine, Mailstop B180, 12631 East 17th Avenue, Aurora, CO, 80045, USA.
VA Eastern Colorado Health Care System, 1055 Clermont Street, Denver, CO, 80207, USA.
J Med Toxicol. 2016 Jun;12(2):148-56. doi: 10.1007/s13181-015-0525-5.
Rates of opioid overdose and opioid-related emergency department (ED) visits have increased dramatically. Naloxone is an effective antidote to potentially fatal opioid overdose, but little is known about naloxone administration in ED settings. We examined trends and correlates of naloxone administration in ED visits nationally from 2000 to 2011. Using data from the National Hospital Ambulatory Medical Care Survey, we examined ED visits involving (1) the administration of naloxone or (2) a diagnosis of opioid overdose, abuse, or dependence. We assessed patient characteristics in these visits, including concomitant administration of prescription opioid medications. We used logistic regression to identify correlates of naloxone administration. From 2000 to 2011, naloxone was administered in an estimated 1.7 million adult ED visits nationally; 19 % of these visits recorded a diagnosis of opioid overdose, abuse, or dependence. An estimated 2.9 million adult ED visits were related to opioid overdose, abuse, or dependence; 11 % of these visits involved naloxone administration. In multivariable logistic regression models, patient age, race, and insurance and non-rural facility location were independently associated with naloxone administration. An opioid medication was provided in 14 % of visits involving naloxone administration. Naloxone was administered in a minority of ED visits related to opioid overdose, abuse, or dependence. Among all ED visits involving naloxone administration, prescription opioids were also provided in one in seven visits. Further work should explore the provider decision-making in the management of opioid overdose in ED settings and examine patient outcomes following these visits.
阿片类药物过量及与阿片类药物相关的急诊科就诊率急剧上升。纳洛酮是治疗潜在致命性阿片类药物过量的有效解毒剂,但对于在急诊科环境中使用纳洛酮的情况却知之甚少。我们研究了2000年至2011年全国急诊科就诊时使用纳洛酮的趋势及相关因素。利用国家医院门诊医疗调查的数据,我们研究了涉及(1)使用纳洛酮或(2)诊断为阿片类药物过量、滥用或依赖的急诊科就诊情况。我们评估了这些就诊患者的特征,包括是否同时使用处方阿片类药物。我们使用逻辑回归来确定与使用纳洛酮相关的因素。2000年至2011年期间,全国估计有170万成年患者在急诊科就诊时使用了纳洛酮;其中19%的就诊记录诊断为阿片类药物过量、滥用或依赖。估计有290万成年患者的急诊科就诊与阿片类药物过量、滥用或依赖有关;其中11%的就诊涉及使用纳洛酮。在多变量逻辑回归模型中,患者年龄、种族、保险情况以及非农村医疗机构地点与使用纳洛酮独立相关。在涉及使用纳洛酮的就诊中,14%的患者还接受了阿片类药物治疗。在与阿片类药物过量、滥用或依赖相关的少数急诊科就诊中使用了纳洛酮。在所有涉及使用纳洛酮的急诊科就诊中,七分之一的就诊还提供了处方阿片类药物。未来的工作应探讨急诊科处理阿片类药物过量时医护人员的决策过程,并检查这些就诊后的患者结局。